TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Alpha Tau Medical Ltd ( (DRTS) ) has issued an update.
On November 20, 2025, Alpha Tau Medical Ltd. announced its third quarter 2025 financial results and provided a corporate update. The company highlighted significant progress, including the commencement of Alpha DaRT pancreatic cancer treatments in a U.S. multi-center pilot study and the receipt of a radioactive material license for its New Hampshire facility, positioning it for commercial readiness. Alpha Tau also reported a cash balance of $75.9 million, supporting ongoing clinical advancements and commercial preparations. The company aims to achieve several milestones in the coming months, such as completing patient recruitment in the U.S. ReSTART trial and receiving a response from Japan’s PMDA regarding marketing authorization for treating recurrent head and neck cancer.
The most recent analyst rating on (DRTS) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Alpha Tau Medical Ltd stock, see the DRTS Stock Forecast page.
Spark’s Take on DRTS Stock
According to Spark, TipRanks’ AI Analyst, DRTS is a Underperform.
Alpha Tau Medical Ltd is struggling with significant financial challenges, primarily due to a lack of revenue and ongoing cash burn. While technical indicators show a neutral trend, the valuation metrics reflect the company’s unprofitability. The absence of earnings call insights and corporate events limits additional context. Overall, the stock is risky with a low score of 38, suggesting caution for potential investors.
To see Spark’s full report on DRTS stock, click here.
More about Alpha Tau Medical Ltd
Alpha Tau Medical Ltd. is an Israeli oncology therapeutics company founded in 2016, focusing on the research, development, and potential commercialization of Alpha DaRT, an innovative alpha-radiation cancer therapy designed for the treatment of solid tumors. The technology was initially developed by professors from Tel Aviv University.
Average Trading Volume: 62,711
Technical Sentiment Signal: Buy
Current Market Cap: $311.7M
See more data about DRTS stock on TipRanks’ Stock Analysis page.